Verelan PM Related Published Studies
Well-designed clinical trials related to Verelan PM (Verapamil)
Need for prophylactic application of verapamil in transradial coronary
procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial
Interventions OmittabLe?) trial. [2014]
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. [2011.08]
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]
The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. [2011.06]
A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. [2011.02.01]
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. [2011.02]
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). [2010.12]
Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. [2010.11.15]
The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, and verapamil on the cardiovascular influences of dexmedetomidine in conscious sheep. [2010.10]
Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). [2010.08.15]
Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease. [2010.04]
Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]
Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma. [2009.11]
Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. [2009.07]
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. [2009.06]
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. [2009.05]
Impact of nitroglycerin and verapamil on coronary arterial distensibility as assessed by intravascular ultrasound. [2009.04]
Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. [2009]
Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. [2008.12]
The effect of oral verapamil on the visual evoked potentials in multiple sclerosis patients. [2008.09]
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). [2008.08]
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]
Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study. [2008]
Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. [2007.11]
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. [2007.08]
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). [2007.06.01]
Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. [2007.05]
Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03.01]
Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. [2007.03]
Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. [2007.03]
Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03]
Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. [2007.01]
Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. [2006.11.15]
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). [2006.10.01]
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. [2006.09.05]
Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. [2006.09]
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. [2006.08]
Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. [2006.08]
Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. [2006.04]
Effects of papaverine and glycerilnitrate-verapamil solution as topical and intraluminal vasodilators for internal thoracic artery. [2006.01]
Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. [2005.11]
Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. [2005.11]
Assessment of the efficacy of phentolamine to prevent radial artery spasm during cardiac catheterization procedures: a randomized study comparing phentolamine vs. verapamil. [2005.10]
A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. [2005.09.15]
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. [2005.07]
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. [2005.05]
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. [2005.01]
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. [2004.07]
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]
Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. [2004.06.16]
Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. [2004.05]
A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. [2004.04]
Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. [2004.02]
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]
[A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia] [2003.11]
Evaluation of i.v. verapamil effects on cardiovascular responses in normotensive patients during laryngoscopy. [2003.10]
VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). [2003.08]
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. [2003.04.23]
Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. [2003.02]
Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. [2002.10]
Oral tizanidine, an alpha2-adrenoceptor agonist, reduces the minimum alveolar concentration of sevoflurane in human adults. [2002.08]
Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. [2002.07]
Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. [2002.06]
Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. [2002.06]
Effects of grapefruit juice and smoking on verapamil concentrations in steady state. [2002.04]
Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. [2002.01]
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. [2002.01]
Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. [2001.12]
VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. [2001.07]
Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. [2001.07]
Topical verapamil in glaucoma filtration surgery. [2001.06]
Effects of verapamil in normal elderly individuals with left ventricular diastolic dysfunction. [2001.02]
Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. [2001.01]
A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. [2001.01]
Less adrenergic response to mental task during verapamil compared to amlodipine treatment in hypertensive subjects. [2001]
Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. [2000.12]
Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure. [2000.12]
A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. [2000.11]
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. [2000.11]
Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies. [2000.08.01]
Brachial plexus anesthesia with verapamil and/or morphine. [2000.08]
Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam, and verapamil. [2000.07]
Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. [2000.06]
Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS). [2000.06]
Early administration of verapamil after thrombolysis in acute anterior myocardial infarction. Effect on left ventricular remodeling and clinical outcome. VAMI Study Group. Verapamil Acute Myocardial Infarction. [2000.05]
Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. [2000.05]
Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition. [2000.05]
Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. [2000.03.28]
Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage. [2000.03]
Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. [2000.03]
Magnesium oxide augmentation of verapamil maintenance therapy in mania. [2000.02.14]
Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. [2000.02]
Effects of fosinopril or sustained-release verapamil on blood pressure and serum catecholamine concentrations in elderly hypertensive men. [2000.01]
Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. [2000]
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. [1999.09]
The effect of verapamil on left ventricular remodelling and diastolic function after acute myocardial infarction (the Verapamil Infarction Study on Remodelling and Relaxation--VISOR). [1999.07]
Comparison of intravenous metoprolol, verapamil and diltiazem on the attenuation of haemodynamic changes associated with tracheal extubation. [1999.07]
|